Vazyme Biotech

Vazyme Biotech is a biotechnology company focused on the research, development, and production of functional proteins like enzymes, antigens, and antibodies. Founded in 2012 by Dr. Cao Lin, a former university professor, the company was born from the need for more accessible and affordable research reagents. Dr. Cao, who holds a Ph.D. from Nanjing University and an EMBA from China Europe International Business School, established Vazyme with a group of like-minded colleagues to develop enzyme-based solutions for technical challenges in the field.

The company operates across several business sectors, including life sciences, in vitro diagnostics (IVD), and biopharmaceuticals. Its business model involves the in-house production and sale of core raw materials and finished products. Revenue streams are primarily generated from product sales, such as reagents and kits for research and clinical diagnostics, and to a lesser extent, from contract research services. Vazyme serves a global clientele that includes over 10,000 business customers, such as biopharmaceutical companies, research institutions, and hospitals across more than 60 countries. A significant milestone was achieved on November 15, 2021, when the company was listed on the Shanghai Stock Exchange's STAR Market (Stock Code: 688105).

Vazyme's product portfolio is extensive, featuring over 200 types of genetically engineered recombinant enzymes, more than 1,000 high-performance antigens and antibodies, and over 500 terminal products. In the life sciences domain, it offers a wide range of molecular biology reagents, including products for PCR, qPCR, cloning, and next-generation sequencing (NGS) library preparation. For the in-vitro diagnostics market, the company provides raw materials and develops diagnostic reagents and equipment for conditions like infectious diseases, cardiovascular diseases, and tumors. Notably, during the COVID-19 pandemic, Vazyme developed and supplied billions of nucleic acid detection raw materials and hundreds of millions of antigen and antibody detection reagents.

Keywords: life sciences, biotechnology, in-vitro diagnostics, molecular biology reagents, recombinant enzymes, antibodies, antigens, biopharmaceuticals, next-generation sequencing, PCR reagents, genetic engineering, medical diagnostics, enzyme technology, drug R&D, clinical diagnostics, research reagents, nucleic acid detection, protein engineering, scientific research, IVD raw materials, healthcare technology, biopharma solutions.